Clinical Trials Browser

Withdrawn × magrolimab × Myeloid × Clear all

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute